Hostname: page-component-76fb5796d-22dnz Total loading time: 0 Render date: 2024-04-25T21:43:36.442Z Has data issue: false hasContentIssue false
  • English
  • Français

Study on the efficacy and tolerability of amisulpride in medical/surgical inpatients with delirium admitted to a general hospital

Published online by Cambridge University Press:  16 April 2020

L. Pintor ,
E. Fuente ,
E. Bailles  and
S. Matrai
L. Pintor*
Affiliation:
Psychiatry Department, Neurosciences Institute, Hospital Clínico de Barcelona, C/Roselló 140, 08036Barcelona, Spain
E. Fuente
Affiliation:
Psychiatry Department, Hospital Duran i Reynals, C/ Autovía de Castelldefells, Km 2.7 Hospitalet de Llobregat, Barcelona, Spain
E. Bailles
Affiliation:
Psychiatry Department, Neurosciences Institute, Hospital Clínico de Barcelona, C/Roselló 140, 08036Barcelona, Spain
S. Matrai
Affiliation:
Psychiatry Department, Neurosciences Institute, Hospital Clínico de Barcelona, C/Roselló 140, 08036Barcelona, Spain
*
*Corresponding author. Psychiatry Department, Neuroscience Institute, Hospital Clínico de Barcelona, C/Villarroel 170, 08036 Barcelona, Spain. Tel.: +34 93 2275477; fax: +34 93 2275477. E-mail address: lpintor@clinic.ub.es
Get access

Abstract

Purpose

To evaluate the efficacy and safety of amisulpride in medical inpatients who present with delirium.

Method

Open label prospective study with 7-day follow-up. Forty hospital inpatients with delirium were recruited, seven of whom died and two of whom refused medication. The average dose of amisulpride for delirium treatment was 200–300 mg/day. Daily assessments were performed with Delirium Rating Scale (DRS), Positive Subscale of the Positive and Negative Syndrome Scale (PANSS-P), Mini Mental State Examination (MMSE), Neurological Subscale of the UKU side effect rating scale. Variance analysis was performed through repeated measurements, with the general linear model with paired comparisons and Bonferroni correction for each measured variable.

Results

Patients showed significant improvement on the DRS from the first day of treatment DRS = 17.55 until day 7 DRS = 7.26 (F = 92.485; p < 0.001), psychotic symptoms improved from first day PANSS-P = 18.26 to last day PANSS-P = 9.35 (F = 144.83; p < 0.001). Cognitive status showed a significant improvement from day 2 MMSE = 18.71 until day 7 MMSE = 24.06 (F = 96.56; p < 0.001), and the neurological subscale of the UKU side effect rating scale showed a significant improvement the last day with respect to baseline pretreatment level (F = 7.539; p = 0.01).

Conclusions

These results suggest a good response to amisulpride in the acute phase of delirium, although further randomized controlled studies must be performed.

Keywords

DeliriumAntipsychoticsEfficacyAmisulpride
Type
Original article
Information
European Psychiatry , Volume 24 , Issue 7 , October 2009 , pp. 450 - 455
Copyright
Copyright © Elsevier Masson SAS 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders DSM IV 4th ed 1994 American Psychiatric Association Washington DCGoogle Scholar
American Psychiatry Association Practice guideline for the treatment of patients with delirium. Am J Psychiatry 1999;156:1–20Google Scholar
Breitbart, WMarotta, RPlatt, MMWeisman, HDerevenco, MGrau, Cet al.A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry 1996;153:231–237Google ScholarPubMed
Bulbena, ACorrons, CAmorós, GMartín-Santos, RAnguiano, BEscalas de Delirium y orientación. Adaptación castellana del Delirium Rating Scale y de la Orientation Scale. Rev Gerontol 1996;6:245–254Google Scholar
Cameron, DJThomas, RIMulvihill, MBronheim, HDelirium: a test of the Diagnostic and Statistical Manual III criteria on medical inpatients. J Am Geriatr Soc 1987;35:1007–1010CrossRefGoogle ScholarPubMed
Cole, MGPrimeau, FJPrognosis of delirium in elderly hospital patients. CMAJ 1993;149:41–46Google ScholarPubMed
Ely, EWShintani, ATruman, BSperoff, TGordon, SMHarrell, FE Jr.et al.Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA 2004;291(14):1753–1762CrossRefGoogle ScholarPubMed
Folstein, MFFolstein, SEMcHugh, PRMini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:218–222Google ScholarPubMed
Gruber-Baldini, ALZimmerman, SMorrison, RSGrattan, LMHebel, JRDolan, MMet al.Cognitive impairment in hip fracture patients: timing of detection and longitudinal follow-up. J Am Geriatr Soc 2003;51:1227–1236CrossRefGoogle ScholarPubMed
Gustafson, YBerggren, DBrännström, BBucht, GNorberg, AHansson, LIet al.Acute confusional states in elderly patients treated for femoral neck fracture. J Am Geriatr Soc 1988;36:525–530CrossRefGoogle ScholarPubMed
Guy W. ECDEU Assesment Manual for Psychofarmacology. US Dept Health, Education, Welfare Publication (ADM) 76–338. Rockville, Md. National Institute of Mental Health; 1976. p. 218–22.Google Scholar
Han, CSKim, YKA double-blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics. 2004;45:297–301CrossRefGoogle ScholarPubMed
Huang, SCTsai, SJChan, CHHwang, JPSim, CBCharacteristics and outcome of delirium in psychiatric inpatients. Psychiatry Clin Neurosci 1998;52:47–50CrossRefGoogle ScholarPubMed
Inouye, SKDelirium in Hospitalized older patients. Clin Geriatr Med 1998;14:745–764CrossRefGoogle ScholarPubMed
Inouye, SKDelirium in Older Persons. N Engl J Med 2006;354:1157–1165CrossRefGoogle ScholarPubMed
Jackson, JCGordon, SMHart, RPHopkins, ROEly, EWThe association between delirium and cognitive decline: a review of the empirical literature. Neuropsychol Rev. 2004;14(2):87–98CrossRefGoogle ScholarPubMed
Jitapunkul, SPillay, IEbrahim, SDelirium in newly admitted elderly patients: a prospective study. Q J Med 1992;83:307–314Google ScholarPubMed
Kay, SRFiszbein, AOpler, LAThe Positive and negative syndrome scale (PANSS) for Schizophrenia. Schizophr Bull 1987;13:261–276CrossRefGoogle Scholar
Kim, KYBader, GMKotlyar, VGropper, DTreatment of delirium in older adults with quetiapine. J Geriatr Psychiatry Neurol 2003;16:29–31CrossRefGoogle ScholarPubMed
Kishi, YKato, MOkuyama, THosaka, TMikami, KMeller, Wet al.Delirium: patients characteristics that predict a missed diagnosis at psychiatric consultation. Gen Hosp Psychiatry 2007;29:442–445CrossRefGoogle ScholarPubMed
Lacasse, HPerreault, MMWilliamson, DRSystematic review of antipsychotics for the treatment of hospital-associated delirium in medically or surgically ill patients. Ann Pharmacother 2006;40:1966–1973CrossRefGoogle ScholarPubMed
Lee, KUWon, WYLee, HKKweon, YSLee, CTPae, CUet al.Amisulpride versus quetiapine for the treatment of delirium: a randomized, open prospective study. Int Clin Psychopharmacol 2005;20:311–314CrossRefGoogle ScholarPubMed
Lingjaerde, OAhlfors, UGBech, PDencker, SJElgen, KThe UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987;334:1–100CrossRefGoogle Scholar
Liptzin, BLevkoff, SEAn empirical study of delirium subtypes. Br J Psychiatry 1992;161:843–845CrossRefGoogle ScholarPubMed
Lobo, ASaz, PMarcos, GDía, JLde la Cámara, CVentura, Tet al.Revalidation and standardization of the cognition mini-exam (first Spanish version of the Mini-Mental Status Examination) in the general geriatric population. Medicina Clinica 1999;112:767–774Google ScholarPubMed
MacLullich, AMBeaglehole, AHall, RJMeagher, DJDelirium and long-term cognitive impairment. Int Rev Psychiatry. 2009;21(1):30–42CrossRefGoogle ScholarPubMed
Miyaji, SYamamoto, KHoshino, SYamamoto, HSakai, YMiyaoka, HComparison of the risk of adverse events between risperidone and haloperidol in delirium patients. Psychiatry Clin Neurosci 2007;61:275–282CrossRefGoogle ScholarPubMed
Pae, CULee, SJLee, CULee, CPaik, IHA pilot trial of quetiapine for the treatment of patients with delirium. Hum Psychopharmacol 2004;19:125–127CrossRefGoogle ScholarPubMed
Parellada, EBaeza, Ide Pablo, JMartínez, GRisperidone in the treatment of patients with delirium. J Clin Psychiatry 2004;65:348–353CrossRefGoogle ScholarPubMed
Peralta, VCuesta, MJValidación de la escala de los síndromes positivo y negativo (PANSS) en una muestra de esquizofrénicos españoles. Actas Luso-Españolas de neurología y Psiquiatría 1994;22:171–177Google Scholar
Pisani, MAInouye, SKMcNicoll, LRedlich, CAScreening for preexisting cognitive impairment in older intensive care unit patients: use of proxy assessment. J Am Geriatr Soc 2003;51:689–693CrossRefGoogle ScholarPubMed
Pun, BTEly, EWThe importance of diagnosing and managing ICU delirium. Chest 2007;132(2):624–636 [Review]CrossRefGoogle ScholarPubMed
Schwartz, TLMasand, PSTreatment of Delirium With Quetiapine. Prim Care Companion J Clin Psychiatry 2000;2:10–12CrossRefGoogle ScholarPubMed
Seeman, PAtypical antipsychotics: Mechanism of action. Can J Psychiatry 2002;47:27–38CrossRefGoogle ScholarPubMed
Skrobik, YKBergeron, NDumont, MGottfried, SBOlanzapine vs haloperidol: treating delirium in a critical care setting. Intensive Care Med 2004;30:444–449Google Scholar
Trzepacz, PTBaker, RWGreenhouse, JA symptom rating scale for delirium. Psychiatry Res 1988;23:89–97CrossRefGoogle ScholarPubMed
Trzepacz, PTMittal, DTorres, RKanary, KNorton, JJimerson, NValidation of the Delirium Rating Scale-revised-98: comparison with the delirium rating scale and the cognitive test for delirium. J Neuropsychiatry Clin Neurosci 2001;13:229–242CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.